oxalomalic-acid and Lung-Neoplasms

Melanoma is the most aggressive skin cancer due to a high propensity for metastasis, with a 10-year survival rate of less than 10%. The devastating clinical outcome and lack of effective preventative therapeutics for metastatic melanoma necessitate the development of new therapeutic strategies targeted to inhibit the regulatory circuits underlying the progression and metastasis of melanoma. Melanoma metastasis requires migration and invasion of the malignant tumour cells driven by proteolytic remodelling of the extracellular matrix (ECM) executed by matrix metalloproteinases (MMPs), particularly MMP-2 and MMP-9. Inhibiting components of these circuits defines new therapeutic opportunities for melanoma with metastatic malignancy. Oxalomalate (OMA) is a competitive inhibitor of NADP

Topics: Animals; Cell Movement; Isocitrate Dehydrogenase; Lung Neoplasms; Male; Melanoma, Experimental; Mice; Mice, Inbred BALB C; Oxalates; Oxidative Stress; Reactive Oxygen Species; Signal Transduction